Reference : Targeting nanoparticles to M cells with non-peptidic ligands for oral vaccination
Scientific journals : Article
Physical, chemical, mathematical & earth Sciences : Chemistry
Engineering, computing & technology : Materials science & engineering
http://hdl.handle.net/2268/19919
Targeting nanoparticles to M cells with non-peptidic ligands for oral vaccination
English
Fievez, Virginie [Université catholique de Louvain (UCL) > > Unité de Pharmacie Galénique (Bruxelles) et Laboratoire de Biochimie cellulaire, toxicologique et nutritionnelle (Louvain-la-Neuve) > >]
Plapied, Laurence [Université catholique de Louvain (UCL),Bruxelles > > Unité de Pharmacie Galénique > >]
des Rieux, Anne [Université catholique de Louvain (UCL), Bruxelles > Unité de Pharmacie Galénique > > >]
Pourcelle, Vincent [Université catholique de Louvain (UCL) > > Unité de Chimie Organique et Médicinale > >]
Freichels, Hélène [University of Liège (ULg) > Department of Chemistry > Center for Education and Research on Macromolecules (CERM) > >]
Wascotte, Valentine [Université catholique de Louvain (UCL), Bruxelles > > Unité de Pharamcie Galénique > >]
Vanderhaegen, Marie-Lyse [Université catholique de Louvain (UCL), Bruxelles > > Unité de Pharamcie Galénique > >]
Jérôme, Christine mailto [University of Liège (ULg) > Department of Chemistry > Center for Education and Research on Macromolecules (CERM) > >]
Vanderplasschen, Alain mailto [University of Liège (ULg) > Département des Maladies infectieuses et parasitaires > Immunologie et vaccinologie > >]
Marchand-Brynaert, Jacqueline [Université catholique de Louvain (UCL) > > Unité de Chimie Organique et Médicinale > >]
Préat, Véronique [Université catholique de Louvain (UCL), Bruxelles > > Unité de Pharmacie Galénique > >]
2009
European Journal of Pharmaceutics & Biopharmaceutics
Elsevier Science
Yes (verified by ORBi)
International
0939-6411
Amsterdam
The Netherlands
[en] biomaterial ; nanomedicine ; organic nanoparticle
[en] The presence of RGD on nanoparticles allows the targeting of β1 integrins at the apical surface of human M cells and the enhancement of an immune response after oral immunization. To check the hypothesis that non-peptidic ligands targeting intestinal M cells or APCs would be more efficient for oral immunization than RGD, novel non-peptidic and peptidic analogs (RGD peptidomimitic (RGDp), LDV derivative (LDVd) and LDV peptidomimetic (LDVp)) as well as mannose were grafted on the PEG chain of PCL–PEG and incorporated in PLGA-based nanoparticles. RGD and RGDp significantly increased the transport of nanoparticles across an in vitro model of human M cells as compared to enterocytes. RGD, LDVp, LDVd and mannose enhanced nanoparticle uptake by macrophages in vitro. The intraduodenal immunization with RGDp-, LDVd- or mannose-labeled nanoparticles elicited a higher production of IgG antibodies than the intramuscular injection of free ovalbumin or intraduodenal administration of either non-targeted or RGD-nanoparticles. Targeted formulations were also able to induce a cellular immune response. In conclusion, the in vitro transport of nanoparticles, uptake by macrophages and the immune response were positively influenced by the presence of ligands at the surface of nanoparticles. These targeted-nanoparticles could thus represent a promising delivery system for oral immunization.
Center for Education and Research on Macromolecules (CERM)
Fonds de la Recherche Scientifique (Communauté française de Belgique) - F.R.S.-FNRS ; Région wallonne : Direction générale des Technologies, de la Recherche et de l'Energie (DGTRE) in the frame of a FIRST EUROPE and VACCINOR (WINNOMAT) projects
Researchers
http://hdl.handle.net/2268/19919
10.1016/j.ejpb.2009.04.009
http://www.sciencedirect.com/science?_ob=MImg&_imagekey=B6T6C-4W6Y7YS-2-H&_cdi=5027&_user=532038&_orig=browse&_coverDate=09%2F30%2F2009&_sk=999269998&view=c&wchp=dGLbVtz-zSkzS&md5=f8143a2902f6cb816085317d826026dc&ie=/sdarticle.pdf
http://www.elsevier.com/wps/find/journaldescription.cws_home/600120/description#description
The authors acknowledge European Journal of Pharmaceutics & Biopharmaceutics (Elsevier) for allowing them to archive this paper.

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
Fievez V 2009 Eur J Pharm Biopharm 10534.pdfPublisher postprint547.31 kBRequest copy
Open access
Fievez V 2009 Eur J Pharm Biopharm 10534.pdfAuthor postprint349.45 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.